What it Takes to Deliver a Cancer Therapy in a Hurricane
Market Watch 09.27.17
Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
PROVENGE® (sipuleucel-T) is a prescription medicine that is used to treat certain patients with advanced prostate cancer. PROVENGE is made from your own immune cells.
You are encouraged to report negative side effects of prescription drugs to the FDA.Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information.
Dendreon Pharmaceuticals LLC is not responsible for the content of other websites or any representations or product descriptions contained therein.
Copyright © 2018 Dendreon Pharmaceuticals LLC. All Rights Reserved. PRV.0310.USA.17